^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KEAP1 mutation + KRAS mutation

    i
    Other names: KEAP1, Kelch Like ECH Associated Protein 1, Cytosolic Inhibitor Of Nrf2, Kelch-Like Family Member 19, Kelch-Like Protein 19, KLHL19, INrf2, KEAP1 Delta C, KIAA0132, INRF2, KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 9817
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over4years
    Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. (PubMed, J Immunother Cancer)
    Though treatment was feasible, due to toxicity the study arm was terminated early by investigator consensus. In light of this, and while the long-term disease-free status of patients who achieved pCR is encouraging, further investigation of neoadjuvant nivolumab plus ipilimumab in patients with resectable NSCLC requires the identification of predictive biomarkers that enrich for response.
    Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • KEAP1 mutation + KRAS mutation • TMB + PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    over4years
    The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. (PubMed, Clin Cancer Res)
    SMARCA4 alterations can be divided into two clinically relevant genomic classes associated with differential protein expression as well as distinct prognostic and treatment implications. Both classes co-occur with KEAP1, STK11, and KRAS mutations, but individually represent independent predictors of poor prognosis. Despite association with poor outcomes, SMARCA4-mutant lung cancers may be more sensitive to immunotherapy.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    KRAS mutation • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • SMARCA4 mutation • KEAP1 mutation + KRAS mutation
    over4years
    [VIRTUAL] Deep targeted and whole exome sequencing identifies driver mutations in the airway epithelium of individuals at high risk for lung cancer (AACR-II 2020)
    This field of cancerization effect may provide a tool for risk assessment for lung cancer. This research was funded by U01CA196405 to PPM.
    Clinical • Tumor Mutational Burden
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation • NF1 mutation • KEAP1 mutation • MET mutation • KEAP1 mutation + KRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over4years
    [VIRTUAL] Association of KEAP1/NFE2L2 mutations with survival and prediction of immunotherapy in patients with non-small cell lung cancer: Results from multicohort study (AACR-II 2020)
    Intervention of immunotherapy reverses poor prognosis of patients with KEAP1/NFE2L2 mutations due to the higher TMB and neoantigen burden. KEAP1/NFE2L2 mutations maybe potential biomarkers for Immunotherapy in NSCLC.
    Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • KRAS mutation • ALK mutation • KEAP1 mutation • NFE2L2 mutation • KEAP1 mutation + KRAS mutation
    over4years
    [VIRTUAL] Mutational landscape of STK11, PD-L1 expression, and TMB in patients with non-small cell lung cancer (AACR-II 2020)
    The results showed that in our cohort, Chinese NSCLC patients with STK11 GAs were enriched in PD-L1-neg/TMB-H subgroup and associated with a poor response to ICIs in Chinese NSCLC patients. We also found that co-mutations of STK11 and KEAP1 may have implications as a negative biomarker for guiding ICI treatment.
    Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • KRAS mutation • TMB-H • STK11 mutation • KEAP1 mutation • KRAS mutation + STK11 mutation • KEAP1 mutation + KRAS mutation